Editas Medicine Inc is a leading biotechnology company specializing in genome editing. As a company, Editas Medicine Inc represents values of innovation, scientific advancement, and patient-centered focus. Their corporate philosophy revolves around the commitment to revolutionize medicine by harnessing the potential of CRISPR technology. By developing novel gene editing therapies, Editas Medicine Inc aims to address previously untreatable genetic diseases and make a positive impact on the lives of patients. The company's dedication to cutting-edge research and collaboration with other industry leaders underscores their mission to provide transformative solutions through precise genomic medicine.

Editas Medicine Inc is primarily present in the United States.

Editas Medicine Inc has achieved several significant milestones in its journey. Notably, the company successfully completed its initial public offering (IPO) in early 2016, raising substantial capital to support its research and development efforts. Additionally, Editas Medicine Inc became the first company to obtain a U.S. FDA Investigational New Drug (IND) clearance for a CRISPR gene-editing therapy called EDIT-101, aimed at treating a rare form of blindness. This achievement marked a groundbreaking advancement in the field of gene therapy. Furthermore, the company has formed strategic partnerships with leading healthcare organizations and pharmaceutical companies, further strengthening its position in the market. Overall, Editas Medicine Inc continues to pave the way for innovative advancements in gene editing and remains dedicated to transforming the future of medicine.

Editas Medicine Inc, founded in 2013, is a leading genome editing company that focuses on translating its CRISPR-based technology into novel therapeutics. The company aims to develop transformative genome editing solutions to treat a wide range of diseases on a genetic level. Editas Medicine has a strong research and development team that works tirelessly to advance its pipeline of potential therapies. With a vision to revolutionize medicine, Editas Medicine strives to bring innovative treatments to patients suffering from debilitating genetic disorders. The company's commitment to cutting-edge technology and groundbreaking research positions Editas Medicine as a pioneering force in the field of genome editing.

The main competitors of Editas Medicine Inc in the market include other companies involved in gene editing and gene therapy research, such as Intellia Therapeutics Inc, CRISPR Therapeutics AG, and Sangamo Therapeutics Inc. These companies also focus on developing therapies aiming to treat genetic diseases and conditions using advanced gene editing technologies. While Editas Medicine Inc has been at the forefront of the gene editing industry, these competitors demonstrate significant potential and innovation in the field, contributing to a competitive landscape that fosters advancements in gene therapy.

Editas Medicine Inc is primarily active in the biotechnology industry.

The business model of Editas Medicine Inc focuses on developing transformative genomic medicines. Editas Medicine is a leading clinical-stage biotechnology company, utilizing its proprietary CRISPR gene editing platform to discover, develop, and deliver innovative therapies to treat a wide range of serious diseases. With a strong emphasis on genetic medicines, Editas Medicine is dedicated to addressing genetic diseases at their source, aiming to provide potential cures or long-term solutions. By leveraging advanced CRISPR technology, Editas Medicine strives to provide life-changing therapies that have the potential to significantly improve patients' lives.

Коефициентът на цена спрямо печалбата (КЦП) на Editas Medicine е -1,90.

Коефициентът на цена към оборот (KUV) на Editas Medicine е 13,08.

AlleAktien качественият резултат за Editas Medicine е 4/10.

очаквана Editas Medicine оборотът е 32,81 млн. USD.

очаквана Editas Medicine печалба е -226,46 млн. USD.

Editas Medicine Inc. is a biopharmaceutical company that focuses on developing therapies for the treatment of genetic diseases. The company utilizes advanced technologies, such as CRISPR/Cas9 genome editing, to develop targeted therapies that are intended to be more effective and safer than traditional treatment methods. Editas is divided into three business areas: ophthalmology, oncology, and rare diseases. In the field of ophthalmology, the company is working on the development of treatments for eye diseases such as Leber congenital amaurosis, an inherited retinal disease that can lead to blindness. The company is also working on treatments for other eye diseases such as retinitis pigmentosa and macular degeneration. Editas also has a portfolio of cancer therapies in the oncology field, including a treatment for blood cancer that targets the specific mutation of cancer cells. The company is also working on treatments for solid tumors, including lung and prostate cancer. In the field of rare diseases, Editas is working on the development of therapies for diseases that are often genetically determined and affect only a small number of patients. The company is focusing on the treatment of muscular dystrophies and hemophilia. To advance its business segments, Editas has established a number of partnerships and financing arrangements. Among its partners are some of the world's leading biopharmaceutical companies, as well as financing institutions that support the company in covering research and development costs. The company is also committed to making gene editing technology more accessible and safer. Editas has filed several patents on CRISPR/Cas9 technology and is working with regulatory authorities to ensure that gene editing is safe and effective. In line with the company's goals of making its technology accessible to the general public, Editas has released a portion of its technologies as open-source software to support researchers around the world in the development of therapies. Editas Medicine Inc. is an emerging force in the field of biopharmaceuticals with a focus on developing therapies for the treatment of genetic diseases. With its emphasis on safety, effectiveness, and transparency, the company has the potential to revolutionize the way we treat diseases.

Editas Medicine разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Editas Medicine в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Editas Medicine е US28106W1036.

WKN на Editas Medicine е A2AC4K.

Тикерът на Editas Medicine е EDIT.

През последните 12 месеца Editas Medicine изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Editas Medicine да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Editas Medicine в момента е .

Editas Medicine изплаща дивидент на тримесечие. Той се разпределя в месеците .

Editas Medicine платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Editas Medicine се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Editas Medicine на 28.07.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 28.07.2024 г..

Последното дивидентно плащане беше извършено на 28.07.2024 г..

През година 2023 Editas Medicine изплати 0 USD под формата на дивиденти.

Дивидентите от Editas Medicine се изплащат в USD.